Thyroid transcription factor-1 expression in colorectal adenocarcinomas

Pathology Research and Practice

Volumn 207, Issue 11, 2011, Pages 686-690

  Dettmer, Matthias ^a   Kim, Tae Eun ^b   Jung, Chan Kwon ^b   Jung, Eun Sun ^b   Lee, Kyo Young ^b   Kang, Chang Suk ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b The Catholic University of Korea   (South Korea)

Author keywords

CDX2 protein; Colorectal cancer; Cytokeratin; Immunohistochemistry; TTF1 protein

Indexed keywords

CYTOKERATIN 20; CYTOKERATIN 7; MONOCLONAL ANTIBODY; MUCIN 2; THYROID TRANSCRIPTION FACTOR 1; TRANSCRIPTION FACTOR CDX2;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER GRADING; CANCER STAGING; CLINICAL ARTICLE; COLORECTAL CARCINOMA; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; PROGNOSIS; PROTEIN ANALYSIS; TISSUE MICROARRAY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 82755188168     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2011.08.009     Document Type: Article

References (30)

1. Barbareschi M., Murer B., Colby T.V., Chilosi M., Macri E., Loda M., Doglioni C. CDX-2 homeobox gene expression is a reliable marker of colorectal adenocarcinoma metastases to the lungs. Am. J. Surg. Pathol. 2003, 27:141-149.
2. Bejarano P.A., Baughman R.P., Biddinger P.W., Miller M.A., Fenoglio-Preiser C., al-Kafaji B., Di Lauro R., Whitsett J.A. Surfactant proteins and thyroid transcription factor-1 in pulmonary and breast carcinomas. Mod. Pathol. 1996, 9:445-452.
3. Bejarano P.A., Mousavi F. Incidence and significance of cytoplasmic thyroid transcription factor-1 immunoreactivity. Arch. Pathol. Lab. Med. 2003, 127:193-195.
4. Boggaram V. Thyroid transcription factor-1 (TTF-1/Nkx2.1/TITF1) gene regulation in the lung. Clin. Sci. (Lond.) 2009, 116:27-35.
5. Butt S.J., Sousa V.H., Fuccillo M.V., Hjerling-Leffler J., Miyoshi G., Kimura S., Fishell G. The requirement of Nkx2-1 in the temporal specification of cortical interneuron subtypes. Neuron 2008, 59:722-732.
6. Carre A., Szinnai G., Castanet M., Sura-Trueba S., Tron E., Broutin-L'Hermite I., Barat P., Goizet C., Lacombe D., Moutard M.L., Raybaud C., Raynaud-Ravni C., Romana S., Ythier H., Leger J., Polak M. Five new TTF1/NKX2.1 mutations in brain-lung-thyroid syndrome: rescue by PAX8 synergism in one case. Hum. Mol. Genet. 2009, 18:2266-2276.
7. Chu P., Wu E., Weiss L.M. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod. Pathol. 2000, 13:962-972.
8. Comperat E., Zhang F., Perrotin C., Molina T., Magdeleinat P., Marmey B., Regnard J.F., Audouin J., Camilleri-Broet S. Variable sensitivity and specificity of TTF-1 antibodies in lung metastatic adenocarcinoma of colorectal origin. Mod. Pathol. 2005, 18:1371-1376.
9. Dabbs D.J. Diagnostic Immunohistochemistry: Theranostic and Genomic Applications 2010, Saunders, Philadelphia, pp. 1-960.
10. Dennis J.L., Hvidsten T.R., Wit E.C., Komorowski J., Bell A.K., Downie I., Mooney J., Verbeke C., Bellamy C., Keith W.N., Oien K.A. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin. Cancer Res. 2005, 11:3766-3772.
11. Folpe A.L., Gown A.M., Lamps L.W., Garcia R., Dail D.H., Zarbo R.J., Schmidt R.A. Thyroid transcription factor-1: immunohistochemical evaluation in pulmonary neuroendocrine tumors. Mod. Pathol. 1999, 12:5-8.
12. Fujiwara S., Nawa A., Nakanishi T., Shimoyama Y., Kajiyama H., Shibata K., Ino K., Nakamura S., Kikkawa F., Yatabe Y. Thyroid transcription factor 1 expression in ovarian carcinomas is an independent prognostic factor. Hum. Pathol. 2010, 41:560-565.
13. Holzinger A., Dingle S., Bejarano P.A., Miller M.A., Weaver T.E., DiLauro R., Whitsett J.A. Monoclonal antibody to thyroid transcription factor-1: production, characterization, and usefulness in tumor diagnosis. Hybridoma 1996, 15:49-53.
14. Jung C.K., Jung J.H., Lee A., Lee Y.S., Choi Y.J., Yoon S.K., Lee K.Y. Diagnostic use of nuclear beta-catenin expression for the assessment of endometrial stromal tumors. Mod. Pathol. 2008, 21:756-763.
15. Khoor A., Whitsett J.A., Stahlman M.T., Olson S.J., Cagle P.T. Utility of surfactant protein B precursor and thyroid transcription factor 1 in differentiating adenocarcinoma of the lung from malignant mesothelioma. Hum. Pathol. 1999, 30:695-700.
16. Kubba L.A., McCluggage W.G., Liu J., Malpica A., Euscher E.D., Silva E.G., Deavers M.T. Thyroid transcription factor-1 expression in ovarian epithelial neoplasms. Mod. Pathol. 2008, 21:485-490.
17. Lau S.K., Desrochers M.J., Luthringer D.J. Expression of thyroid transcription factor-1, cytokeratin 7, and cytokeratin 20 in bronchioloalveolar carcinomas: an immunohistochemical evaluation of 67 cases. Mod. Pathol. 2002, 15:538-542.
18. Lee M.J., Lee H.S., Kim W.H., Choi Y., Yang M. Expression of mucins and cytokeratins in primary carcinomas of the digestive system. Mod. Pathol. 2003, 16:403-410.
19. Mazziotta R.M., Borczuk A.C., Powell C.A., Mansukhani M. CDX2 immunostaining as a gastrointestinal marker: expression in lung carcinomas is a potential pitfall. Appl. Immunohistochem. Mol. Morphol. 2005, 13:55-60.
20. McCluggage W.G., Kennedy K., Busam K.J. An immunohistochemical study of cervical neuroendocrine carcinomas: neoplasms that are commonly TTF1 positive and which may express CK20 and P63. Am. J. Surg. Pathol. 2010, 34:525-532.
21. Mourra N., Bengrine-Lefevre L. TTF-1 positivity in metastatic colorectal carcinoma: a diagnostic pitfall in transbronchial biopsy. Appl. Immunohistochem. Mol. Morphol. 2010, 18:574-576.
22. Nguyen M.D., Plasil B., Wen P., Frankel W.L. Mucin profiles in signet-ring cell carcinoma. Arch. Pathol. Lab. Med. 2006, 130:799-804.
23. Nobrega-Pereira S., Kessaris N., Du T., Kimura S., Anderson S.A., Marin O. Postmitotic Nkx2-1 controls the migration of telencephalic interneurons by direct repression of guidance receptors. Neuron 2008, 59:733-745.
24. Park S.Y., Kim B.H., Kim J.H., Lee S., Kang G.H. Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma. Arch. Pathol. Lab. Med. 2007, 131:1561-1567.
25. Penman D., Downie I., Roberts F. Positive immunostaining for thyroid transcription factor-1 in primary and metastatic colonic adenocarcinoma: a note of caution. J. Clin. Pathol. 2006, 59:663-664.
26. Saad R.S., Cho P., Silverman J.F., Liu Y. Usefulness of Cdx2 in separating mucinous bronchioloalveolar adenocarcinoma of the lung from metastatic mucinous colorectal adenocarcinoma. Am. J. Clin. Pathol. 2004, 122:421-427.
27. Scarpatetti M., Tsybrovskyy O., Popper H.H. Cytokeratin typing as an aid in the differential diagnosis of primary versus metastatic lung carcinomas, and comparison with normal lung. Virchows Arch. 2002, 440:70-76.
28. Siami K., McCluggage W.G., Ordonez N.G., Euscher E.D., Malpica A., Sneige N., Silva E.G., Deavers M.T. Thyroid transcription factor-1 expression in endometrial and endocervical adenocarcinomas. Am. J. Surg. Pathol. 2007, 31:1759-1763.
29. Werling R.W., Yaziji H., Bacchi C.E., Gown A.M. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. Am. J. Surg. Pathol. 2003, 27:303-310.
30. Xu B., Thong N., Tan D., Khoury T. Expression of thyroid transcription factor-1 in colorectal carcinoma. Appl. Immunohistochem. Mol. Morphol. 2010, 18:244-249.